Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18586692 | 0.80 | RAB9A (0.55) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL12298063 | 0.80 | RAB9A (0.55) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10661576 | 0.79 | RAB9A (0.53) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL5113969 | 0.77 | RAB9A (0.52) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL31559974 | 0.77 | RAB9A (0.55) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL14644365 | 0.77 | RAB9A (0.55) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL20542272 | 0.77 | RAB9A (0.55) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL23046953 | 0.76 | RAB9A (0.50) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL20031299 | 0.76 | RAB9A (0.50) | RAB9APOLBHPGDSNPC1SMN1; SMN2 | |
| SCHEMBL28114539 | 0.75 | RAB9A (0.53) | RAB9APOLBHPGDSNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | disclosed |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | NPY5R, NPY1R, NPY2R | RAB9A 3171/4885POLB 4242/4885HPGDS 933/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | RAB9A 2741/4885POLB 4332/4885HPGDS 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.